Radboud University Medical Center (Nijmegen, NL) has initiated a clinical trial using the CLS TRANBERG® products for patients with prostate cancer

Lund, Sweden, 18 February, 2022 – Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.

“I am very pleased that the Minimally Invasive Image-Guided Intervention Center (MAGIC) at Radboudumc, a leading European center in diagnosis and treatment of prostate cancer, has chosen to collaborate with CLS in this clinical investigation into the safety and feasibility of MR guided FLA as a focal therapy treatment of patients with localized prostate cancer, using our TRANBERG® products that integrates with their MR-scanner and robotic system for procedure imaging, navigation and monitoring of the entire procedure”, says Lars-Erik Eriksson, Deputy CEO of CLS.

“My team is looking forward to this clinical study in collaboration with CLS within our clinical trial on magnetic resonance (MR) guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized low to intermediate risk prostate cancer”, says Professor Jurgen Fütterer from MAGIC at Radboudumc. “The study will investigate a minimally invasive MR guided laser ablation procedure, to remove the index tumor that is confined to the prostate gland. With this new technology of CLS, that fully integrates with our MR-scanner and robotic system for accessing the prostate, the MR-guided procedure is performed using a much less invasive approach, compared to surgery, while still offering a high degree of precision and accuracy during instrument positioning and tumor ablation.”


About localized prostate cancer

About 1,700,000 new cases per year of localized prostate cancer are reported worldwide. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.

This information is information that CLS AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on February 18, 2022 at 16:45 CET.


Contact information:
Lars-Erik Eriksson, CFO and Deputy CEO, Clinical Laserthermia Systems AB (publ).

Phone: +46 – (0)702 – 90 33 00
E-mail: lars-erik.eriksson@clinicallaser.com

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region